Associated Papers
Advances in the diagnosis and treatment of MET-variant digestive tract tumors.
Zhang C et al.
World Journal of Gastrointestinal Oncology, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
Recording and classifying MET receptor mutations in cancers.
Guérin C et al.
Elife, 2024
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y et al.
Respiratory Research, 2023
An In silico Approach towards Finding the Cancer-Causing Mutations in Human MET Gene.
Laskar FS et al.
International Journal of Genomics, 2023
Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.
Sebai M et al.
Human Mutation, 2022
A full-proteome, interaction-specific characterization of mutational hotspots across human cancers.
Chen S et al.
Genome Research, 2022
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Lee M et al.
Expert Opinion on Therapeutic Targets, 2021
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.
Miao W et al.
Cancer Science, 2019
Reproducible Analysis of Post-Translational Modifications in Proteomes--Application to Human Mutations.
Holehouse AS et al.
Plos One, 2015
MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
Albiges L et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Yan SB et al.
Investigational New Drugs, 2013
The role of the c-Met pathway in lung cancer and the potential for targeted therapy.
Sattler M et al.
Therapeutic Advances in Medical Oncology, 2011
Inhibitory effect of c-Met mutants on the formation of branching tubules by a porcine aortic endothelial cell line.
Maemura M et al.
Cancer Science, 2006
Different point mutations in the met oncogene elicit distinct biological properties.
Giordano S et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2000
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
Michieli P et al.
Oncogene, 1999